DocDollars

Neurocrine Biosciences, Inc.

CA · United States · Reporting entity ID 100000186746

Total reported 2019–2025
$131.3M
#78 of 2,960 reporting companies — 0.2% of all reported industry payments
$83.0M in general payments across 484,660 records, plus $48.3M in research funding across 11,916 records.

How it breaks down

General payments $82,981,703
Research funding $48,301,792

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Neurocrine Biosciences, Inc. reported $131.3M to US doctors and teaching hospitals from 2019 to 2025, ranking #78 of 2,960 reporting companies. 37% of that was research funding and 63% general payments such as consulting, speaking, food and travel. 484,660 general payment records and 11,916 research records were filed.

Common questions about Neurocrine Biosciences, Inc.

How much has Neurocrine Biosciences, Inc. paid US doctors?

Neurocrine Biosciences, Inc. reported $131,283,495 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $82,981,703 in general payments, $48,301,792 in research funding.

How does Neurocrine Biosciences, Inc. rank among drug and device companies?

It ranks #78 of 2,960 reporting entities by total reported value, about 0.2% of all industry payments in the dataset.

Does a payment from Neurocrine Biosciences, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.